2019年CSCO BC指南更新要点解读

Update and interpretation of 2019 guideline of Chinese Society of Clinical Oncology (CSCO):Breast cancer

基于循证医学证据、兼顾诊疗产品的可及性、吸收精准医学新进展是中国临床肿瘤学会指南制定的首要标准。结合这样的标准,在2018版CSCO BC指南的基础上,结合临床研究进展,融入真实世界数据,结合临床实践经验,更新形成了2019年CSCO BC指南。新版指南对乳腺癌新辅助治疗、辅助治疗、解救治疗、治疗管理做了较大幅度修改,同时新增了液体活检、二代测序、人工智能等新章节,更加全面的指导乳腺癌临床工作。该文对2019年CSCO BC指南更新要点作解读。

Evidence-based medicine, accessibility of diagnostic and therapeutic products, and new advances in precise medicine are the first standards by guidelines of Chinese Society of Clinical Oncology. Under this circumstance, the 2019 CSCO BC guideline was updated based on high quality clinical researches, real world data and clinical experiences. The new edition of the guideline has made considerable modifications in neoadjuvant therapy, adjuvant therapy, rescue therapy and treatment management of breast cancer. At the same time, new chapters such as liquid biopsy, next generation sequencing and artificial intelligence have been added to guide the clinical work of breast cancer comprehensively.